曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 3550人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648104, encodeId=0dc61648104aa, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！, objectType=article, longId=106025, objectId=664e1060250f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=664e1060250f, replyNumber=0, likeNumber=85, createdTime=2018-03-12, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=664e1060250f, moduleTitle=NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=664e1060250f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648101, encodeId=4a111648101ae, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索, objectType=article, longId=98467, objectId=81bc9846eef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81bc9846eef, replyNumber=0, likeNumber=59, createdTime=2018-04-26, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81bc9846eef, moduleTitle=JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81bc9846eef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648098, encodeId=601616480986d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet：HERA 研究 11 年随访：曲妥珠单抗可提高 Her2 阳性乳腺癌生存, objectType=article, longId=92706, objectId=edf692e06e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf692e06e3, replyNumber=0, likeNumber=69, createdTime=2017-12-15, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf692e06e3, moduleTitle=Lancet：HERA 研究 11 年随访：曲妥珠单抗可提高 Her2 阳性乳腺癌生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf692e06e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648109, encodeId=f5a11648109b4, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=【CSCO 2017】令人振奋：曲妥珠单抗治疗晚期胃癌生存期可达30个月, objectType=article, longId=114765, objectId=fa54114e6577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa54114e6577, replyNumber=0, likeNumber=70, createdTime=2018-06-06, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa54114e6577, moduleTitle=【CSCO 2017】令人振奋：曲妥珠单抗治疗晚期胃癌生存期可达30个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa54114e6577)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648102, encodeId=3e6b1648102a3, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：Her-2阳性胃或胃食管结合部腺癌：标准治疗vs高剂量的曲妥珠单抗联合化疗（IIIb期多中心随机研究）, objectType=article, longId=101489, objectId=321410148959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=321410148959, replyNumber=0, likeNumber=79, createdTime=2017-06-19, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=321410148959, moduleTitle=JCO：Her-2阳性胃或胃食管结合部腺癌：标准治疗vs高剂量的曲妥珠单抗联合化疗（IIIb期多中心随机研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=321410148959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648105, encodeId=e9171648105e4, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：曲妥珠单抗联合化疗方案孰优孰劣？, objectType=article, longId=106280, objectId=211d106280ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211d106280ea, replyNumber=0, likeNumber=67, createdTime=2017-08-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211d106280ea, moduleTitle=JCO：曲妥珠单抗联合化疗方案孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211d106280ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648096, encodeId=ee471648096ba, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, objectType=article, longId=83429, objectId=1e488342901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e488342901, replyNumber=0, likeNumber=64, createdTime=2017-10-08, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e488342901, moduleTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e488342901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648100, encodeId=a61a164810056, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果, objectType=article, longId=93431, objectId=b62a93431e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b62a93431e2, replyNumber=0, likeNumber=66, createdTime=2017-12-20, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b62a93431e2, moduleTitle=Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b62a93431e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648095, encodeId=3a611648095e6, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：肌钙蛋白可预测早期乳腺癌接受曲妥珠单抗治疗时的心脏毒性风险, objectType=article, longId=81376, objectId=72bf813e604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72bf813e604, replyNumber=0, likeNumber=88, createdTime=2017-04-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72bf813e604, moduleTitle=JCO：肌钙蛋白可预测早期乳腺癌接受曲妥珠单抗治疗时的心脏毒性风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72bf813e604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648097, encodeId=d1b1164809e54, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？, objectType=article, longId=89829, objectId=3ab989829c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ab989829c3, replyNumber=0, likeNumber=69, createdTime=2017-06-28, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ab989829c3, moduleTitle=LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ab989829c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648093, encodeId=cc75164809318, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=生物仿制药ABP 980与曲妥珠单抗具有可比性, objectType=article, longId=73516, objectId=3333e3516ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3333e3516ba, replyNumber=0, likeNumber=70, createdTime=2017-05-05, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3333e3516ba, moduleTitle=生物仿制药ABP 980与曲妥珠单抗具有可比性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3333e3516ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648094, encodeId=c594164809402, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=CIRC RES：多柔比星和曲妥珠单抗诱导的心肌功能障碍预测新指标—免疫球蛋白E, objectType=article, longId=81290, objectId=e9db8129011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9db8129011, replyNumber=0, likeNumber=60, createdTime=2017-08-17, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9db8129011, moduleTitle=CIRC RES：多柔比星和曲妥珠单抗诱导的心肌功能障碍预测新指标—免疫球蛋白E, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9db8129011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648092, encodeId=0778164809253, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur J Cancer：曲妥珠单抗治疗转移性乳腺癌时的心脏毒性情况, objectType=article, longId=62244, objectId=ccad62244e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccad62244e2, replyNumber=0, likeNumber=0, createdTime=2016-12-23, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccad62244e2, moduleTitle=Eur J Cancer：曲妥珠单抗治疗转移性乳腺癌时的心脏毒性情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccad62244e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, objectType=article, longId=48932, objectId=982548932ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982548932ef, replyNumber=0, likeNumber=79, createdTime=2016-01-23, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982548932ef, moduleTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982548932ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648090, encodeId=49c2164809095, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：曲妥珠单抗联合紫杉醇在Ⅰ期HER2(+)乳腺癌患者中的治疗, objectType=article, longId=45494, objectId=283b45494c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=283b45494c5, replyNumber=0, likeNumber=76, createdTime=2015-05-13, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=283b45494c5, moduleTitle=NEJM：曲妥珠单抗联合紫杉醇在Ⅰ期HER2(+)乳腺癌患者中的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=283b45494c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648089, encodeId=da821648089aa, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：紫杉醇+曲妥珠单抗可改善＜3cm的HER2+乳腺癌预后, objectType=article, longId=45384, objectId=a3e845384ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3e845384ae, replyNumber=0, likeNumber=62, createdTime=2015-02-04, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3e845384ae, moduleTitle=NEJM：紫杉醇+曲妥珠单抗可改善＜3cm的HER2+乳腺癌预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3e845384ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648088, encodeId=7759164808857, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Onco Targets Ther：曲妥珠单抗治疗乳腺癌一定会有心脏毒性吗？, objectType=article, longId=42642, objectId=f96e42642ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e42642ea, replyNumber=0, likeNumber=0, createdTime=2015-05-26, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e42642ea, moduleTitle=Onco Targets Ther：曲妥珠单抗治疗乳腺癌一定会有心脏毒性吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e42642ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648087, encodeId=536f164808ebb, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究), objectType=article, longId=36148, objectId=d495361484d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d495361484d, replyNumber=0, likeNumber=85, createdTime=2014-07-27, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d495361484d, moduleTitle=ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d495361484d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648086, encodeId=f29216480860c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：曲妥珠单抗治疗的乳腺癌老龄患者充血性心力衰竭发生率较高, objectType=article, longId=26239, objectId=4ee32623946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee32623946, replyNumber=0, likeNumber=66, createdTime=2013-11-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee32623946, moduleTitle=JCO：曲妥珠单抗治疗的乳腺癌老龄患者充血性心力衰竭发生率较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee32623946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648085, encodeId=790d1648085e6, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考, objectType=article, longId=21786, objectId=571b21e8663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=571b21e8663, replyNumber=0, likeNumber=79, createdTime=2014-03-14, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=571b21e8663, moduleTitle=曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=571b21e8663)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

智慧医人 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！

2018-03-12

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索

2018-04-26

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet：HERA 研究 11 年随访：曲妥珠单抗可提高 Her2 阳性乳腺癌生存

2017-12-15

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

【CSCO 2017】令人振奋：曲妥珠单抗治疗晚期胃癌生存期可达30个月

2018-06-06

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：Her-2阳性胃或胃食管结合部腺癌：标准治疗vs高剂量的曲妥珠单抗联合化疗（IIIb期多中心随机研究）

2017-06-19

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：曲妥珠单抗联合化疗方案孰优孰劣？

2017-08-22

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？

2017-10-08

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果

2017-12-20

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：肌钙蛋白可预测早期乳腺癌接受曲妥珠单抗治疗时的心脏毒性风险

2017-04-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？

2017-06-28

hb2008ye (审核中...)

前往app查看评论内容

#曲妥珠#

生物仿制药ABP 980与曲妥珠单抗具有可比性

2017-05-05

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

CIRC RES：多柔比星和曲妥珠单抗诱导的心肌功能障碍预测新指标—免疫球蛋白E

2017-08-17

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur J Cancer：曲妥珠单抗治疗转移性乳腺癌时的心脏毒性情况

2016-12-23

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期

2016-01-23

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：曲妥珠单抗联合紫杉醇在Ⅰ期HER2(+)乳腺癌患者中的治疗

2015-05-13

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：紫杉醇+曲妥珠单抗可改善＜3cm的HER2+乳腺癌预后

2015-02-04

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Onco Targets Ther：曲妥珠单抗治疗乳腺癌一定会有心脏毒性吗？

2015-05-26

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究)

2014-07-27

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：曲妥珠单抗治疗的乳腺癌老龄患者充血性心力衰竭发生率较高

2013-11-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考

2014-03-14

科室
- - 订阅+
  - 更多科室
工具
服务